BR112022021879A2 - Conjugados de decorina guiados por peptídeos de homing para uso no tratamento de epidermólise bolhosa - Google Patents
Conjugados de decorina guiados por peptídeos de homing para uso no tratamento de epidermólise bolhosaInfo
- Publication number
- BR112022021879A2 BR112022021879A2 BR112022021879A BR112022021879A BR112022021879A2 BR 112022021879 A2 BR112022021879 A2 BR 112022021879A2 BR 112022021879 A BR112022021879 A BR 112022021879A BR 112022021879 A BR112022021879 A BR 112022021879A BR 112022021879 A2 BR112022021879 A2 BR 112022021879A2
- Authority
- BR
- Brazil
- Prior art keywords
- treatment
- decorin
- guided
- epidermolysis bullosa
- conjugates
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4725—Proteoglycans, e.g. aggreccan
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1019—Tetrapeptides with the first amino acid being basic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dermatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Marine Sciences & Fisheries (AREA)
- Toxicology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063016359P | 2020-04-28 | 2020-04-28 | |
| FI20205431 | 2020-04-28 | ||
| PCT/FI2021/050318 WO2021219940A1 (en) | 2020-04-28 | 2021-04-28 | Homing peptide-guided decorin conjugates for use in treating epidermolysis bullosa |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022021879A2 true BR112022021879A2 (pt) | 2022-12-20 |
Family
ID=75870661
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022021879A BR112022021879A2 (pt) | 2020-04-28 | 2021-04-28 | Conjugados de decorina guiados por peptídeos de homing para uso no tratamento de epidermólise bolhosa |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20230167162A1 (https=) |
| EP (1) | EP4142771A1 (https=) |
| JP (1) | JP7824885B2 (https=) |
| KR (1) | KR20230005314A (https=) |
| CN (1) | CN115605218B (https=) |
| AU (1) | AU2021266157A1 (https=) |
| BR (1) | BR112022021879A2 (https=) |
| CA (1) | CA3180694A1 (https=) |
| IL (1) | IL297703A (https=) |
| WO (1) | WO2021219940A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN118001404B (zh) * | 2024-02-06 | 2025-02-25 | 四川大学华西医院 | 抑制C17orf67基因表达试剂在制备治疗获得性大疱表皮松解症药物中的用途 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008136869A2 (en) | 2006-12-06 | 2008-11-13 | Burnham Institute For Medical Research | Methods and compositions related to targeting wounds, regenerating tissue, and tumors |
-
2021
- 2021-04-28 BR BR112022021879A patent/BR112022021879A2/pt unknown
- 2021-04-28 IL IL297703A patent/IL297703A/en unknown
- 2021-04-28 EP EP21724346.8A patent/EP4142771A1/en active Pending
- 2021-04-28 CA CA3180694A patent/CA3180694A1/en active Pending
- 2021-04-28 JP JP2022563981A patent/JP7824885B2/ja active Active
- 2021-04-28 KR KR1020227041682A patent/KR20230005314A/ko active Pending
- 2021-04-28 CN CN202180031725.5A patent/CN115605218B/zh active Active
- 2021-04-28 WO PCT/FI2021/050318 patent/WO2021219940A1/en not_active Ceased
- 2021-04-28 AU AU2021266157A patent/AU2021266157A1/en active Pending
- 2021-04-28 US US17/997,428 patent/US20230167162A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN115605218A (zh) | 2023-01-13 |
| CA3180694A1 (en) | 2021-11-04 |
| JP2023523719A (ja) | 2023-06-07 |
| WO2021219940A1 (en) | 2021-11-04 |
| AU2021266157A1 (en) | 2022-12-08 |
| CN115605218B (zh) | 2026-03-24 |
| JP7824885B2 (ja) | 2026-03-05 |
| EP4142771A1 (en) | 2023-03-08 |
| IL297703A (en) | 2022-12-01 |
| US20230167162A1 (en) | 2023-06-01 |
| KR20230005314A (ko) | 2023-01-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12019502278A1 (en) | Conjugation of a cytotoxic drug with bis-linkage | |
| MX2021004069A (es) | Enlazadores de conjugacion que contienen el grupo 2,3-diaminosuccinilo. | |
| BR112022002599A2 (pt) | Vesícula extracelular ligada a moléculas e usos da mesma | |
| EP3949969A3 (en) | Benzazepine compounds, conjugates, and uses thereof | |
| MX2023001466A (es) | Enlazadores de base peptidica. | |
| MX2020006192A (es) | Un conjugado de un analogo de tubulisina con enlazadores ramificados. | |
| BR112016024363A2 (pt) | conjugado de anticorpo-fármaco e seu uso para tratamento de câncer | |
| CO2023016246A2 (es) | Composiciones inmunógenas que comprenden antígenos de sacárido capsular conjugados y sus usos | |
| MX2022000037A (es) | Enlazadores hidrofilicos para conjugados de peptidos multivalentes. | |
| MX2022003268A (es) | Liberacion selectiva de farmaco a partir de conjugados internalizados de compuestos biologicamente activos. | |
| PE20161209A1 (es) | Conjugados de anticuerpos anti-drosophila similar a delta 3 (anti-dll3) y medicamentos para usarse en el tratamiento contra melanoma | |
| ES2585328T3 (es) | Variantes no lipidadas de antígenos ORF2086 de Neisseria meningitidis | |
| EA202192137A1 (ru) | Конъюгат аматоксинового аналога с разветвленными линкерами | |
| GEAP202316334A (en) | Nanoemulsion adjuvant composition for pneumococcal conjugate vaccines | |
| BR112022002720A2 (pt) | Formulações de conjugados de benzazepinas e usos das mesmas | |
| BR112022005026A2 (pt) | Conjugados terapêuticos | |
| AR052541A1 (es) | Vacunas de glicoconjugados que contiene peptidoglicina | |
| BR112018011177A2 (pt) | conjugados de citarabina para terapia de câncer | |
| BRPI0519583A2 (pt) | composiÇço cosmÉtica apropriada para relaxar rugas de expressço, e, mÉtodo para tratamento cosmÉtico para relaxamento de rugas | |
| BRPI0513145A (pt) | conjugados de amino, aminoácido ou peptìdeo de ácido retinóico | |
| BR112022021879A2 (pt) | Conjugados de decorina guiados por peptídeos de homing para uso no tratamento de epidermólise bolhosa | |
| BR112022024691A2 (pt) | Conjugados anticorpo biespecífico - fármaco direcionados a egfr e muc1 e usos dos mesmos | |
| WO2021211683A3 (en) | Compositions and methods for targeted therapeutic delivery to bone | |
| BR112022013255A2 (pt) | Conjugados anticorpo-fármaco específicos de sítio com ligantes contendo peptídeo | |
| MX2023015471A (es) | Conjugados de anticuerpo-farmaco que comprenden anticuerpos humanizados que eligen como blanco la proteina asociada al receptor activador de plasminogeno tipo uroquinasa (uparap). |